Impact of Elexacaftor/Tezacaftor/Ivacaftor on Systemic Antibiotic Utilization in Pediatric Patients with Cystic Fibrosis

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Systemic Antibiotic Utilization in Pediatric Patients with Cystic Fibrosis | Authorea try { document.documentElement.classList.add('js'); } catch (e) { } var _gaq = _gaq || []; _gaq.push(['_setAccount', 'G-8VDV14Y67G']); _gaq.push(['_trackPageview']); (function() { var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true; ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s); })(); Skip to main content Preprints Collections Wiley Open Research IET Open Research Ecological Society of Japan All Collections About About Authorea FAQs Contact Us Quick Search anywhere Search for preprint articles, keywords, etc. Search Search ADVANCED SEARCH SCROLL This is a preprint and has not been peer reviewed. Data may be preliminary. 30 September 2025 V1 Latest version Share on Impact of Elexacaftor/Tezacaftor/Ivacaftor on Systemic Antibiotic Utilization in Pediatric Patients with Cystic Fibrosis Authors : Julianne Fava 0009-0005-2023-276X [email protected] , Emily M. Stephan , Jessica Tansmore , Shahid Sheikh 0000-0003-0944-5076 , Mariah Eisner , and Kimberly Novak Authors Info & Affiliations https://doi.org/10.22541/au.175924453.34433040/v1 221 views 140 downloads Contents Abstract Supplementary Material Information & Authors Metrics & Citations View Options References Figures Tables Media Share Abstract Introduction: Cystic fibrosis (CF) is an autosomal recessive disease resulting from mutations in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene. Recurrent respiratory infections are a common problem, and patients receive frequent antibiotics. Treatment of CF involves both symptomatic and underlying disease-targeting therapies. Elexacaftor/tezacaftor/ivacaftor (ETI), a disease-targeting therapy, combines two correctors and a potentiator to increase functioning of the CFTR channel. With better functioning channels, symptomatic improvement is expected in the form of decreased respiratory infections. Objective: To evaluate the change in antibiotic use following the initiation of ETI therapy in pediatric patients. Methods: This is a single-center, retrospective chart review conducted at Nationwide Children’s Hospital (NCH) in Columbus, Ohio. Patients served as self-controls, compared before and after initiating ETI. The primary outcome was change in antibiotic days per patient-year. Secondary outcomes included change in specific antibiotic use, enteral versus intravenous therapy, and different classes of antibiotics. The study was approved by the NCH IRB. Results: 139 patients were included. The median antibiotic days per patient-year was 17 days pre-ETI and 6 days post-ETI (p<0.001). There was a significant decrease in antibiotic days per patient-year for intravenous antibiotics, enteral antibiotics, intravenous vancomycin, linezolid/tedizolid, anti-methicillin-resistant Staphylococcus aureus (MRSA) tetracyclines, other anti-MRSA medications (clindamycin and sulfamethoxazole-trimethoprim), aminoglycosides, anti- Pseudomonas aeruginosa (PSAE) beta-lactams, and fluoroquinolones. There was no significant difference in carbapenems or non-anti-PSAE beta-lactams. Conclusion: ETI therapy was associated with decreased antibiotic days for many therapeutic classes of both enteral and intravenous antibiotics. Supplementary Material File (trikafta manuscript 9-29-25.docx) Download 37.18 KB Information & Authors Information Version history V1 Version 1 30 September 2025 Copyright This work is licensed under a Non Exclusive No Reuse License. Keywords antibiotics cystic fibrosis elexacaftor/tezacaftor/ivacaftor infection respiratory Authors Affiliations Julianne Fava 0009-0005-2023-276X [email protected] Nationwide Children's Hospital View all articles by this author Emily M. Stephan Nationwide Children's Hospital View all articles by this author Jessica Tansmore Nationwide Children's Hospital View all articles by this author Shahid Sheikh 0000-0003-0944-5076 Nationwide Children's Hospital View all articles by this author Mariah Eisner Abigail Wexner Research Institute at Nationwide Children's Hospital View all articles by this author Kimberly Novak Nationwide Children's Hospital View all articles by this author Metrics & Citations Metrics Article Usage 221 views 140 downloads .FvxKWukQNSOunydq8rnd { width: 100px; } Citations Download citation Julianne Fava, Emily M. Stephan, Jessica Tansmore, et al. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Systemic Antibiotic Utilization in Pediatric Patients with Cystic Fibrosis. Authorea . 30 September 2025. DOI: https://doi.org/10.22541/au.175924453.34433040/v1 If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download. For more information or tips please see 'Downloading to a citation manager' in the Help menu . Format Please select one from the list RIS (ProCite, Reference Manager) EndNote BibTex Medlars RefWorks Direct import Tips for downloading citations document.getElementById('citMgrHelpLink').addEventListener('click', function() { popupHelp(this.href); return false; }); $(".js__slcInclude").on("change", function(e){ if ($(this).val() == 'refworks') $('#direct').prop("checked", false); $('#direct').prop("disabled", ($(this).val() == 'refworks')); }); View Options View options PDF View PDF Figures Tables Media Share Share Share article link Copy Link Copied! Copying failed. Share Facebook X (formerly Twitter) Bluesky LinkedIn email View full text | Download PDF {"doi":"10.22541/au.175924453.34433040/v1","type":"Article"} Now Reading: Share Figures Tables Close figure viewer Back to article Figure title goes here Change zoom level Go to figure location within the article Download figure Toggle share panel Toggle share panel Share Toggle information panel Toggle information panel Go to previous graphic Go to next graphic Go to previous table Go to next table All figures All tables View all material View all material xrefBack.goTo xrefBack.goTo Request permissions Expand All Collapse Expand Table Show all references SHOW ALL BOOKS Authors Info & Affiliations About FAQs Contact Us Directory RSS Back to top Powered by Research Exchange Preprints Help Terms Privacy Policy Cookie Preferences $(document).ready(() => setTimeout(() => { let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" ")); $.get("/resource/lodash?t="+_bnt); },4000)); (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'a00474ec5c74e2c5',t:'MTc3OTU0MzQ2MQ=='};var a=document.createElement('script');a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();